CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled
Drug / intervention
Mirikizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04004611
NCT04004611Phase 2Completed
CompareCT.gov

A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis

Eli Lilly and Company·interventional·Posted Jul 2, 2019·Updated Mar 26, 2024

In Brief

A Phase 2 clinical trial evaluating Mirikizumab for Ulcerative Colitis. Completed, enrolled 26 participants across 37 sites in 5 countries.

Detailed Summary

This study was designed to evaluate how the body processes and removes mirikizumab. The study also evaluated safety and disease response in pediatric participants with UC taking mirikizumab. The study lasted about 52 weeks and included up to 18 visits.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesCanada, Israel, Japan, South Korea, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 2, 2019
Enrollment StartMay 18, 2020
Primary CompletionMar 15, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 7 years ago

Interventions

Mirikizumabdrug

Administered IV and SC